All In Biotech

Drug Trial Radar · NCT00674921

Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda

Last checked: Nov 20, 2026Latest source record: Jun 5, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,650 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,650

Planned (sponsor's estimate)

Start

Jun 2008

Primary completion

Jun 2011

Study completion Jun 2011

Sponsor

Lead sponsor
MRC/UVRI and LSHTM Uganda Research UnitAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medical Research Council
First posted
May 8, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 16 years, up to 59 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

According to the national guidelines in Uganda and to the World Health Organization guidelines, HIV-infected patients should receive cotrimoxazole prophylaxis indefinitely. There are, however, concerns regarding the indefinite application of cotrimoxazole prophylaxis among patients immunologically stabilized on HAART (e.g. high pill burden, drug-drug interactions, toxicity and poor adherence because of treatment fatigue). To date no empirical evidence is available regarding the safety and optimal timing for the cessation of cotrimoxazole prophylaxis among HAART patients who successfully restored immunological competence. Research question: Does morbidity significantly differ between continuation (orthodox) and cessation (experimental) of cotrimoxazole prophylaxis among immuno-competent patients stable HAART in the resource-limited setting of Uganda?

Conditions

  • HIV Infections

Interventions

  • cotrimoxazoleDrug

    cotrimoxazole 800/160 mg once daily as indicated by the start and end times of the specified arms for continued prevention of HIV-related infections

  • PlaceboDrug

    starch, magnesium stearate, sodium lauryl sulphate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. all-cause morbidity such as pneumonia or malaria (presumptive and definitive diagnosis)Time frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • MRC/UVRI Uganda Research Unit on Aids

    Entebbe, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.